A phase I open-labeled, dose-escalation, safety study of the combination of Velcade [bortezomib] and chemoradiation for the treatment of cancer patients.

Trial Profile

A phase I open-labeled, dose-escalation, safety study of the combination of Velcade [bortezomib] and chemoradiation for the treatment of cancer patients.

Completed
Phase of Trial: Phase I

Latest Information Update: 12 May 2017

At a glance

  • Drugs Antineoplastics; Bortezomib
  • Indications Cervical cancer; CNS cancer; Head and neck cancer; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 19 Aug 2010 Actual end date (Jun 2010) added as reported by ClinicalTrials.gov.
    • 19 Aug 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 05 Jul 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top